cervical cancer

Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Endpoints
Sun, 01/30/22 - 11:42 am
Sanofi
Regeneron
Libtayo
cervical cancer
post-marketing studies
Immuno-oncology spotlight falls on cervical cancer
EP Vantage
Tue, 12/7/21 - 10:39 am
immuno-oncology
cervical cancer
Opdivo
Keytruda
Bristol Myers Squibb
Merck
HPV vaccines reduce cervical cancer by 87%: study
Biopharma Reporter
Thu, 11/4/21 - 10:50 am
HPV
vaccines
cervical cancer
RWE
Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
Fierce Biotech
Fri, 10/22/21 - 11:26 am
Agenus
cervical cancer
balstilimab
Merck
Merck carves out path in first-line advanced cervical cancer with new FDA win for Keytruda juggernaut
Endpoints
Wed, 10/13/21 - 10:48 pm
Merck
Keytruda
FDA
cervical cancer
Regeneron Could Have a Big Catalyst Coming in 2022
Motley Fool
Sat, 10/9/21 - 11:11 pm
Regeneron
Libtayo
cervical cancer
FDA
Sanofi
FDA hands accelerated nod to Seagen, Genmab's solo ADC in cervical cancer, but combo studies look even more promising
Endpoints
Mon, 09/20/21 - 11:01 pm
Seagen
Genmab
Tivdak
FDA
accelerated approval
cervical cancer
Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push
Endpoints
Sat, 09/18/21 - 08:29 pm
ESMO
Merck
Keytruda
Roche
Avastin
cervical cancer
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Fierce Biotech
Sat, 08/28/21 - 09:06 pm
Agenus
FDA
balstilimab
cervical cancer
clinical trials
Merck's Keytruda extends life for cervical cancer patients in first-in-class win
Fierce Pharma
Tue, 06/22/21 - 12:29 pm
Merck
Keytruda
cervical cancer
clinical trials
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Pharma Times
Mon, 03/15/21 - 10:48 am
Sanofi
Regeneron
Libtayo
cervical cancer
clinical trials
Seattle Genetics/Genmab's tisotumab’s cervical cancer efficacy falls off
EP Vantage
Tue, 06/30/20 - 10:34 am
cervical cancer
tisotumab vedotin
Genmab
Seattle Genetics
clinical trials
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
EP Vantage
Fri, 01/24/20 - 10:50 am
Genmab
tisotumab vedotin
cervical cancer
Zogenix
Fintepla
Lennox-Gastaut Syndrome
Just One HPV Dose May Be Enough To Prevent Several Cancers
Forbes
Wed, 07/31/19 - 11:57 pm
vaccines
HPV
Merck
Gardasil
cervical cancer
Emboldened by ASCO data, FDA etches speedy approval path for Iovance's cervical cancer therapy
Endpoints
Tue, 07/2/19 - 10:20 am
FDA
cervical cancer
Iovance
LN-145
Genmab files for $500M IPO to fund multi-front cancer R&D push
Fierce Biotech
Wed, 05/29/19 - 10:02 am
Genmab
IPOs
antibody-drug conjugate
cervical cancer
3 Biotech Stocks That Soared Last Week
Motley Fool
Sun, 05/19/19 - 04:02 pm
Adverum Biotechnologies
ADVM-022
Iovance
LN-145
cervical cancer
MeiraGTx
AAV-RPE65
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Wed, 05/15/19 - 11:52 pm
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven
Advaxis suffers another blow as FDA puts phase 3 on partial hold
Fierce Biotech
Thu, 01/24/19 - 10:53 am
Advaxis
vaccines
FDA
clinical trials
axalimogene filolisbac
cervical cancer
AI device could be cheaper and more accurate than pap smear tests
Pharmaforum
Wed, 11/14/18 - 10:30 am
Lancor Scientific
artificial intelligence
pap smears
diagnostics
cervical cancer

Pages